News
CCXI
--
0.00%
--
ChemoCentryxs Oral PD-L1 inhibitor, CCX559, Featured in Poster Presentation at the 2021 American Association for Cancer Research (AACR) Annual Meeting
GlobeNewswire · 2d ago
ChemoCentryx Says Co's Oral PD-L1 Inhibitor CCX559, Featured In Poster Presentation At 2021 American Association For Cancer Research Annual Meeting
ChemoCentryx, Inc., (NASDAQ:CCXI), today announced that the Company's orally-administered small molecule PD-L1 inhibitor, CCX559, will be featured in a poster presentation at the virtual 2021 Annual Meeting of the
Benzinga · 2d ago
Anca Vasculitis Drug Market Research Report- COVID-19 Analysis Based on Professional and Consumer End-users to 2027
Apr 09, 2021 (Market Insight Reports) -- The latest report as Anca Vasculitis Drug Market acknowledges Size, Application Segment, Type, Regional Outlook,...
Market Insight Reports · 2d ago
C-X-C Chemokine Receptor Type 2 Market Professional Survey, Growth, Shares, Opportunities and Forecast to 2027
Apr 08, 2021 (Market Stats News via COMTEX) -- The latest report as C-X-C Chemokine Receptor Type 2 Market acknowledges Size, Application Segment, Type,...
Market Stats News · 3d ago
C-C Chemokine Receptor Type 4 Market Research Report: By Equipment Type, Refrigerant Type, Application - Global Industry Analysis and Growth Forecast to 2027
Apr 08, 2021 (Market Insight Reports) -- The latest report as C-C Chemokine Receptor Type 4 Market acknowledges Size, Application Segment, Type, Regional...
Market Insight Reports · 3d ago
ChemoCentryx to Host Virtual R&D Day on April 14, 2021
MOUNTAIN VIEW, Apr 07, 2021 (GLOBE NEWSWIRE via COMTEX) -- MOUNTAIN VIEW, Calif., April 07, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI),...
GlobeNewswire · 4d ago
Atypical Hemolytic Uremic Syndrome Drug Market Research Report by Type, by Product, by Application - Global Forecast to 2027 - Cumulative Impact of COVID-19
Apr 06, 2021 (Market Insight Reports) -- CANADA - QYResearchMedical recently added a research report, Atypical Hemolytic Uremic Syndrome Drug market – global...
Market Insight Reports · 5d ago
Anca Vasculitis Drug Market Challenges, Business Opportunities, Current Trends and Industry Analysis 2020-2027 by Ameco Research
pune, India, Tue, 30 Mar 2021 02:30:14 / Comserve Inc. / -- The "Anca Vasculitis Drug Market: Global Industry Trends, Share, Size, Growth, Opportunity and...
Comserve · 03/31 13:09
Shares of CCXI Down 11.6% Since Downtrend Call on Shares
Mar 26, 2021 (SmarTrend(R) Spotlight via COMTEX) -- SmarTrend identified a Downtrend for Chemocentryx Inc (NASDAQ:CCXI) on March 5th, 2021 at $56.40. In...
marketwatch.com · 03/26 17:59
Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size, Share & Trends Analysis Report by Type, by Application, by End Use and Segment Forecasts 2026 || Tokio Marine Holdings, COMPLEXA INC, RETROPHIN INC, BECKMAN COULTER INC. (DANAHER)
Mar 24, 2021 (Market Insight Reports) -- Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Research Report 2020-2026 shares a versatile...
Market Insight Reports · 03/24 06:03
Global Anca Vasculitis Drug Market Size, Share, Revenue, Sale And Growth Rate Beyond Expectations Till 2030
Mar 24, 2021 (WiredRelease via Comtex) -- Let’s reset for growth beyond coronavirus with Market.Biz. Global Anca Vasculitis Drug Market Research report...
marketresearch.biz · 03/24 04:15
Atypical Hemolytic Uremic Syndrome Drug Market Size, Share | Global Industry Report 2020-2027 |Ameco Research
pune, India, Tue, 23 Mar 2021 07:07:46 / Comserve Inc. / -- The global Atypical Hemolytic Uremic Syndrome Drug Market is expected to grow at a significant...
Comserve · 03/23 11:08
Global Venous Leg Ulcers Treatment Market Insights, Overview, Analysis and forecast 2021
Mar 23, 2021 (Heraldkeepers) -- Global Venous Leg Ulcers Treatment Market Overview:Global Venous Leg Ulcers Treatment Market Report 2020 comes with the...
Heraldkeepers · 03/23 04:38
Strength Seen in ChemoCentryx (CCXI): Can Its 8.6% Jump Turn into More Strength?
Zacks.com · 03/22 20:01
Vasculitis – Pipeline Insight, 2021
Mar 18, 2021 (Heraldkeepers) -- DelveInsight's, "Vasculitis - Pipeline Insight, 2021," report provides comprehensive insights about 10+ companies and 10+...
Heraldkeepers · 03/18 13:43
APOL-1 Mediated Kidney Disease Market Growth Reliant on Discovery of Advanced Therapeutics: FMI Study
MarketersMedia · 03/18 01:45
Atypical Chemokine Receptor 3 Market Size Report 2021 by Manufacturer Share, Price, Revenue, Gross Profit and Forecast to 2025
Mar 17, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry." “Atypical Chemokine Receptor 3 Market”...
The Express Wire · 03/17 10:35
Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size, Demand-sales, Suppliers By Key Applications Detailed Analysis and Growth Aspects on Manufacturing Landscapes
Japan, Japan, Thu, 11 Mar 2021 02:11:44 / Comserve Inc. / -- The report analyze market size, share, growth, trends, segmentation, top key players,...
Comserve · 03/11 07:14
8-K: ChemoCentryx, Inc.
(EDGAR Online via COMTEX) -- false 0001340652 0001340652 2021-03-02 2021-03-02 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 03/08 19:45
BRIEF-ChemoCentryx Announces Appointment Of Susan Kanaya To Board
reuters.com · 03/08 13:51
Webull provides a variety of real-time CCXI stock news. You can receive the latest news about ChemoCentryx through multiple platforms. This information may help you make smarter investment decisions.
About CCXI
ChemoCentryx, Inc. is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact. Its late stage compounds include Avacopan (CCX168) and CCX140. Avacopan (CCX168) is an orally administered complement inhibitor targeting the C5a receptor (C5aR), and is being developed for orphan and rare diseases, including anti-neutrophil cytoplasmic auto-antibody associated vasculitis (AAV); atypical hemolytic uremic syndrome (aHUS), and complement 3 glomerulopathy (C3G). CCX140 is an orally administered inhibitor of the chemokine receptor known as C-C chemokine receptor type 2 (CCR2), in development for diabetic nephropathy (DN), a form of chronic kidney disease (CKD), and for focal segmental glomerulosclerosis (FSGS).